Frontier IP Group Plc, through its subsidiaries, identifies and evaluates commercialization of intellectual property generated by academics, universities, and other partners in the United Kingdom. It also provides investment advisory and marketing services. The company was incorporated in 2007 and is based in London, the United Kingdom.

Frontier IP Group Plc

Frontier IP Group Plc focuses on commercialising intellectual property from research, utilizing expertise in various fields to co-found and develop innovative businesses.

Frontier IP Group plc | 922 followers on LinkedIn. We build value by uniting science, industry and finance to commercialise university intellectual property | Frontier IP specialises in the commercialisation of 
Intellectual Property (IP).
 
Frontier IP establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and help maximise the commercial value of technologies emerging from their research programmes.
 
Frontier IP Group plc is quoted on the AIM market.

Independent Non-Executive Director

Nigel Grierson

Chief Commercialisation Officer at Frontier IP Group plc

Matthew White

Wilson BioPharma Consulting

Campbell Wilson

Finance Director at Frontier IP Group plc

Jim Fish

Frontier IP Group plc

The Vaccine Group and the UK government's Animal and Plant Health Agency have been awarded an Innovate UK Smart grant to develop vaccines against two commercially damaging cattle diseases. Watch TVG CEO Dr Jeremy Salt discuss the project and other developments at the company. #brsv #lumpyskindisease TVG #animalhealth https://lnkd.in/eH2BQ5hj

Great to see our portfolio company The Vaccine Group partnering with the UK government's Animal and Plant Health Agency. They have been awarded an Innovate UK Smart grant to develop cattle vaccines. Initial target diseases are bovine respiratory syncytial virus (BRVS) and lumpy skin disease. Both cause significant economic damage to beef and dairy farmers worldwide. You can learn more here: https://lnkd.in/eHGdMk4q #iuk #innovateuk #brsv #lumpyskindisease #apha #defra

Watch The Vaccine Group CEO Jeremy Salt discuss how a UK government grant will help the company and its partners at the University of Plymouth and the University of Cambridge tackle a bacterial disease in pigs that can also prove fatal in humans. https://lnkd.in/e5vSs-7F #streptococcus #tvg #zoonotic

Our portfolio company The Vaccine Group has teamed up with the University of Plymouth and the University of Cambridge to develop a vaccine to combat a widespread, economically harmful and zoonotic pig disease, which can be fatal to humans. Streptococcus suis is a bacterial infection which is endemic in the global pig population. It can cause meningitis and sceptacaemia in humans. The project is being supported by a grant of more than £1 million from Defra 's Farming Innovation Programme, delivered by Innovate UK. #innovateUK #defra #streptococcus #vaccines #tvg https://lnkd.in/e45pFxRE

We are delighted that Nesta Impact Investments, the investment arm of UK social innovation agency Nesta, has supported our portfolio company Nandi Proteins. Nesta #foodingredients #innovation https://lnkd.in/e7RviH6g

Watch Pulsiv Chief Product Officer Dr Tim Moore discuss the potential for the company's groundbreaking technology with Proactive's Stephen Gunnion: https://lnkd.in/gfC9YkMX #usbc #energyefficiency #pulsiv Proactive Oakglen Wealth Tim tells Proactive’s Stephen Gunnion about the groundbreaking technology behind its latest release—the world’s most efficient 65-watt USB-C reference design charger. Moore detailed how Pulsiv’s focus on maximising power conversion efficiency has led to a cooler-running, more reliable charging solution. He emphasised that the charger’s design, which significantly reduces inrush current, ensures both the safety and longevity of the product, making it ideal for in-socket applications. Tim also discussed the broader market potential, especially as new EU regulations make USB-C connectors mandatory across a wide range of devices. Pulsiv’s technology not only supports these evolving standards but also positions itself as a key player in the fast-growing fast-charger market. As Tim explained, consumers are likely to demand faster charging times across various cordless products, driving the need for high-power USB-C supplies like Pulsiv’s 65W charger. In addition to USB-C applications, Moore hinted at future advancements in AC to DC conversion, which could impact sectors like solar power generation. The conversation highlights Pulsiv’s innovative approach to power conversion, promising a safer and more efficient future for electronic devices.

Listen to Pulsiv chairman Mark Gerhard explain why he thinks the company is Arm 2.0 at an Oakglen Wealth Invest in Innovation seminar earlier this year: https://lnkd.in/gUyzq7Gs Pulsiv has launched the world's most efficient 65W USB-C charger reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. But Pulsiv's underlying technology can be used much more widely, to improve the efficiency of power conversion across a host of different applications. It can also boost output from solar cells. #usbc #energyefficiency

Our portfolio company Pulsiv is today launching the world's most efficient 65W USB-C reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. #pulsiv #usb -c #energyefficiency https://lnkd.in/eGrYDFeA

Metric
Company Name	Frontier IP Group Plc
Symbol	FIPP
MSH ID	UK:CO:FRONTIERIP
Market	STOCKS
Sector	Financial Services
Industry	Asset Management
Country	GB
Stage
Employee Count	21
Website	frontierip.co.uk
LinkedIn
Founders

Metric
Market Cap	243.77K
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	470.21K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.45M
EBITDA	-1.44M
Operating Income	-5.59M
Net Income	-4.10M
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.97
Operating Profit Margin	-8.98
EBITDA Margin	-3.06
Net Profit Margin	-5.44
Return on Equity	-0.04
Return on Assets	-0.04
Return on Capital Employed	-0.07

FIPP

UK:CO:FRONTIERIP

Frontier IP Group Plc

Last Close

29.00

25/11 09:23

Market Cap

194.56K

Beta: -

Volume Today

49.24K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	64.92
EV Multiple	-5.72

Metric
Days Sales Outstanding
Days Payables Outstanding	5.53
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-12.81K
Asset Turnover	0.01

Metric
Operating Cash Flow	-4.11M
Free Cash Flow	-4.13M
Cash Flow to Debt
Operating Cash Flow/Sales	-8.65
Free Cash Flow Yield	-0.12

Metric
Cash & Equivalents	5.82M
Accounts Receivable	32.86K
Inventory
Goodwill	2.49M
Debt to Capitalization
Debt to Assets
Current Ratio	26.65
Quick Ratio	12.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.42
R&D to Revenue
SG&A to Revenue	1.87